Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,478,583 papers from all fields of science
Search
Sign In
Create Free Account
MLN0128
Known as:
MLN-0128
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
INK128
Sapanisertib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract P6-21-08: Synergistic anti-cancer activity of cyclin-dependent kinase 4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing triple negative breast cancer
Takuro Yamamoto
,
N. Kanaya
,
G. Somlo
,
Shiuan Chen
Poster Session Abstracts
2019
Corpus ID: 164556514
Background No targeted therapies have been approved for triple negative breast cancer (TNBC) thus far. Retinoblastoma protein…
Expand
2017
2017
EXTH-58. EFFECTS OF TORC1/2 INHIBITOR MLN0128 ALONE AND IN COMBINATION WITH MEK INHIBITION IN BRAF MUTATED GLIOMA MODELS IN VITRO AND IN VIVO
Kevin X. Liu
,
S. Mueller
,
+6 authors
D. Haas-Kogan
2017
Corpus ID: 79824856
2016
2016
Abstract P5-03-14: MLN0128 regulates survival signaling by AKT and its downstream effectors in HER2+ breast cancer model
P. De
,
J. Carlson
,
+4 authors
B. Leyland-Jones
2016
Corpus ID: 57592385
Evading apoptosis is considered to be a hallmark of cancers including breast cancer, since mutations in apoptotic regulators…
Expand
2015
2015
Abstract 1940: Dual inhibition of mTORC1/C2 and HER2 results in maximal antitumor efficacy in preclinical model of HER2+ breast cancer resistant to trastuzumab therapy
P. De
,
Yuliang Sun
,
J. Carlson
,
Xiaoqian Lin
,
N. Dey
,
B. Leyland-Jones
2015
Corpus ID: 79392674
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Background: Approximately 30% of HER2+ breast…
Expand
2015
2015
A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in…
A. Olszanski
,
M. Middleton
,
+6 authors
T. Macarulla
2015
Corpus ID: 77375762
TPS2609 Background: Signaling hyperactivation secondary to MAPK pathway aberrations are common. RAF kinases play key roles in the…
Expand
2015
2015
Abstract P6-11-09: A preclinical study to demonstrate the utility of fulvestrant and MLN0128 combination against HR+ and HER2+ breast cancer
S. Wu
,
Hannah Lu
,
+6 authors
Shiuan Chen
2015
Corpus ID: 74005903
Background: Up to 10% of total breast cancers are positive for both hormone receptor [HR: estrogen receptor (ER) and/or…
Expand
2015
2015
Small Molecule Therapeutics MLN 0128 , an ATP-Competitive mTOR Kinase InhibitorwithPotent InVitro and InVivo Antitumor Activity , as Potential Therapy for Bone and Soft-Tissue Sarcoma
E. Slotkin
,
Parag P. Patwardhan
,
S. D. Vasudeva
,
E. Stanchina
,
W. Tap
,
G. Schwartz
2015
Corpus ID: 15288426
The mammalian target of rapamycin (mTOR) is a serine/ threonine protein kinase that exists in two complexes (mTORC1 and mTORC2…
Expand
2014
2014
Abstract 4906: mTOR kinase inhibition enhances radiosensitivity in glioblastoma
A. Tandle
,
P. Tofilon
,
K. Camphausen
2014
Corpus ID: 73268687
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor and predicts a poor prognosis despite current…
Expand